The company has also expanded its headquarters and device development facilities, which are now located in Cambourne Business Park, also in Cambridge.

PlaqueTec is leading biomarker-based cardiovascular disease (CVD) research and is building a large database of CVD biology to transform care of people with coronary artery disease. The company was originally established 10 years ago within the Royal Papworth Hospital’s Cardiothoracic Bioincubator facility, which will soon relocate to the Cambridge Biomedical Campus.

PlaqueTec CEO Annalisa Jenkins said: “We are so grateful for the past decade at Papworth, where we were able to develop our unique catheter device in close cooperation with world leading interventional cardiologists. These moves all come at the perfect time as the communal facility at the Babraham Research Campus will help us expedite development of our CVD biomarker database and drive a new era of personalised medicine for people at high risk of heart attack.”

About Cardiovascular Disease

According to the World Health Organization (WHO), cardiovascular disease (CVD) is the world’s number one cause of death. An estimated 17.7 million people died from CVD in 2015, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary artery disease (CAD) and 6.7 million were due to stroke.

CAD is the narrowing or blockage of the coronary arteries, usually caused by a build-up of cholesterol in fatty deposits (plaques) within the inner walls of the arteries. Currently, the biology of CVD is not well known, and there it is impossible to predict which patients are at high risk of a heart attack. New disease detection and treatment approaches are desperately needed.

Source: Company Press Release